The Valley Desk

ArticleJapanese journal of clinical oncologyPublished

Japanese subgroup analysis of AQUILA trial: daratumumab vs active monitoring in high-risk smoldering multiple myeloma

Read the publication ↗

Regional connection

Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source

Publication record

Type
Article
Venue
Japanese journal of clinical oncology
Published
Subject terms
Japan; risk factors; Disease Progression; Smoldering Multiple Myeloma; Daratumumab
PubMed ID
42747040
Added to directory
Source checked

Report a correction or request removal